SINGAPORE -- U.S.-based bio-performance company GreenLight Biosciences has raised an additional $17 million from new and existing investors, including Malaysian private investment company Xeraya Capital, Baird Capital and global investment company Flu Lab, according to a media statement.
The investment was made through Greenlight Pandemic Response, a special purpose vehicle of GreenLight Biosciences, Xeraya Capital CEO Fares Zahir told DealStreetAsia.
